SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Oracle Corporation (NYSE: ORCL) common stock between June 12, 2025 and December 16, 2025. Oracle is a technology company that provides, among other things, infrastructure for operating artificial intelligence (“AI”) programs. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The All ...

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process of its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1][2]. Group 1: Allegations and Issues - Robbins LLP is investigating claims that Inovio misled investors by failing to disclose deficiencies in the manufacturing of the CELLECTRA device, which impacted the timeline for submitting the INO-3107 BLA to the FDA [2]. - The complaint states that Inovio was unlikely to submit the INO-3107 BLA by the second half of 2024 due to these manufacturing issues and lacked sufficient information to justify eligibility for FDA accelerated approval [2]. - The overall regulatory and commercial prospects of INO-3107 were allegedly overstated by the company [2]. Group 2: Stock Price Impact - Following a press release on August 8, 2024, revealing a delay in the submission timeline for the INO-3107 BLA to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [3]. - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline rather than an accelerated one, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio Pharmaceuticals and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. for allegedly being involved in a fraudulent stock promotion scheme that misled investors [2][4]. Group 1: Allegations - The lawsuit claims that Picard Medical failed to disclose that it was the subject of a fraudulent stock promotion scheme involving misinformation on social media and impersonated financial professionals [2]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [2]. Group 2: Stock Price Impact - On October 24, 2025, Picard's stock price experienced a significant crash of 70%, dropping to $3.99 per share [3]. - Following the crash, the company's share price has continued to decline, reaching approximately $2.00 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by April 3, 2026 [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4].

Core Viewpoint - A class action has been filed against Ramaco Resources, Inc. for allegedly overstating development progress at its Brook Mine, with claims that no significant mining activity has occurred since its groundbreaking [1][2]. Group 1: Allegations and Investigations - Robbins LLP is investigating allegations that Ramaco Resources, Inc. failed to disclose the lack of significant mining activity at the Brook Mine after its groundbreaking [2]. - A report by Wolfpack Research claims that the Brook Mine is a "hoax" and that no active mining has taken place, supported by drone footage showing no work occurring three months post-groundbreaking [3]. - Following the report, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025 [3]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Ramaco Resources, Inc., with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for participation [5].

SAN DIEGO, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Richtech Robotics Inc. (NASDAQ: RR) securities between January 27, 2026 and 12:00 PM EST on January 29, 2026. Richtech describes itself as a “robotics and artificial intelligence (“AI”) technology company focused on developing advanced embodied AI systems that aims to improve the efficiency and productivity of U.S. businesses.” For ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company misled investors regarding the results of its Phase 3 studies for setrusumab, which did not meet primary endpoints, leading to significant stock price decline [1] Group 1: Allegations and Misleading Information - The lawsuit claims that Mereo BioPharma provided investors with overly optimistic statements about the Phase 3 ORBIT and COSMIC studies for setrusumab, suggesting confidence in its efficacy in reducing annualized fracture rates [1] - It is alleged that while making positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 programs, which ultimately did not achieve their primary endpoints [1] Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's American Depository Shares (ADS) plummeted from $2.31 to $0.29, representing a decline of over 87.7% [1]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024, and January 23, 2026, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against BlackRock TCP - The complaint alleges that during the class period, BlackRock TCP failed to disclose that its investments were not being timely or appropriately valued [2]. - It is claimed that the company's portfolio restructuring efforts were ineffective in resolving challenged credits or improving portfolio quality [2]. - The lawsuit asserts that the company's unrealized losses were understated, leading to an overstatement of the company's net asset value (NAV) [2]. - As a result of these issues, the positive statements made by the defendants about the company's business and prospects were materially misleading [2]. Group 2: Financial Disclosure and Impact - On January 23, 2026, BlackRock TCP disclosed that its NAV per share as of December 31, 2025, was between $7.05 and $7.09, which is 19% lower than the previous quarter and 23.4% lower than the previous year [3]. - Following this disclosure, BlackRock TCP's stock price dropped by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026 [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by April 6, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, alleging that the company misled investors regarding the Phase III Orbit and Cosmic Studies for setrusumab [1][2]. Allegations - The lawsuit claims that during the class period, Ultragenyx provided investors with overly positive information about the expected results of the Phase III Orbit and Cosmic Studies, which tested setrusumab in patients with Osteogenesis Imperfecta (OI) [2]. - Defendants allegedly expressed confidence in setrusumab's ability to reduce the annualized fracture rate in OI patients and in the study designs to demonstrate this ability, while concealing material adverse facts about the drug's true potential and the risks associated with the study protocols [3]. Study Results and Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action against Ultragenyx are encouraged to contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [5].

Core Viewpoint - A class action has been filed against Plug Power Inc. for allegedly misleading investors regarding its ability to secure and utilize a $1.66 billion loan from the U.S. Department of Energy (DOE) [1] Company Overview - Plug Power Inc. specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets in North America and Europe, including hydrogen storage, production equipment, and infrastructure development [1] Allegations - The complaint alleges that Plug Power overstated the likelihood of receiving funds from the DOE Loan and the construction of necessary hydrogen production facilities [1] - It is claimed that the company was likely to pivot towards less ambitious projects with lower commercial potential [1] Financial Impact - On November 10, 2025, Plug Power reported financial results indicating an expectation to generate over $275 million in liquidity, leading to the suspension of activities under the DOE loan program [1] - Following this announcement, Plug Power's stock price fell by $0.09 per share (3.39%) to close at $2.53 on November 11, 2025 [1] - After confirming the suspension of plans to construct six hydrogen production facilities, the stock price dropped by $0.48 per share (17.58%) to close at $2.25 on November 14, 2025 [1] Class Action Participation - Shareholders interested in serving as lead plaintiffs must file by April 3, 2026, but participation is not required for recovery eligibility [1]

Group 1 - A class action lawsuit has been filed against Plug Power Inc. for allegedly misleading investors about its ability to receive and utilize a $1.66 billion loan from the U.S. Department of Energy (DOE) [1] - The lawsuit covers investors who purchased Plug Power securities between January 17, 2025, and November 13, 2025, and claims that the company overstated the likelihood of accessing the DOE loan funds [1] - Following the announcement of financial results on November 10, 2025, Plug Power's stock price fell by $0.09 per share, or 3.39%, closing at $2.53 per share [1] - On November 13, 2025, it was reported that Plug Power suspended its plans to construct six hydrogen production facilities, leading to a further decline in stock price by $0.48 per share, or 17.58%, closing at $2.25 per share [1] Group 2 - Robbins LLP is also involved in class action lawsuits for other companies, including Picard Medical, Inc. and Richtech Robotics Inc., indicating a broader trend of shareholder litigation in various sectors [2]